Journal of Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology. Read more.
Collections open for submissions
Clinical trials: Phase I, II, and III
Journal of Hematology & Oncology is calling for submissions to our Collection on 'Clinical trials: Phase I, II, and III.' As clinical trials lead the way for novel therapies, we welcome contributions on diverse topics such as novel agents, innovative trial designs, and biomarker development.
Latest updates from major conferences
This Journal of Hematology & Oncology and Experimental Hematology & Oncology series intends to publish Correspondences with latest updates on novel agents and regimens from major conferences on blood and cancer disorders. Each Correspondence serves as a summary and analysis of 5 or more abstracts on a similar focus from a major international conference.
Articles
-
-
Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy
-
The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives
-
Recent advances in S-palmitoylation and its emerging roles in human diseases
-
Recent advances in universal chimeric antigen receptor T cell therapy
-
Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options
-
The effects of β-glucan on human immune and cancer cells
-
The diagnosis and management of NK/T-cell lymphomas
-
NK cell-based cancer immunotherapy: from basic biology to clinical development
-
Wnt/beta-catenin pathway: modulating anticancer immune response
Aims and scope
Experimental Hematology & Oncology
Submit your research to our companion journal, Experimental Hematology & Oncology.
CAHON: Stop hate crimes and racism
The Chinese American Hematologist and Oncologist Network (CAHON) has published an important and timely Editorial in the Journal of Hematology & Oncology. We are proud to stand with them in denouncing in the strongest terms all forms of discrimination and crimes against any racial/ethnic group, including Asian Americans and Pacific Islanders, and to call on our readers to pursue racial equality and tolerance in the USA and beyond.
Editor's quote
"Journal of Hematology & Oncology provides a forum for top-quality research and is a leading title in hematology and oncology, with an Impact Factor ranked in Q1 in both categories. The journal also publishes reviews and research highlights from leading experts in the field. Research is shared with fast turnaround times in an open access format among laboratory scientists, physician scientists, hematologists and oncologists."
Prof Delong Liu, Editor-in-Chief, Journal of Hematology & Oncology
-
Official journal of
-
Journal of Hematology & Oncology is the official journal of the Chinese American Hematologist and Oncologist Network.
-
- Editorial Board
- Manuscript editing services
- Instructions for Editors
- Instructions for authors
- Sign up for article alerts and news from this journal
Follow
Annual Journal Metrics
-
Citation Impact
Journal Impact Factor: 40.4 (2024)
5-year Journal Impact Factor: 34.4 (2024)
Source Normalized Impact per Paper (SNIP): 6.040 (2024)
SCImago Journal Rank (SJR): 10.192 (2024)Speed
Submission to first editorial decision (median days): 4
Submission to acceptance (median days): 61Usage 2024
Downloads: 3,430,659
Altmetric mentions: 1,308
Institutional membership
Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).